文章名稱引用次數(shù)

• Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association47
• Severe hypertriglyceridemia is primarily polygenic34
• Review of current evidence and clinical recommendations on the effects of low- carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force25
• Clinical and biochemical features of different molecular etiologies of familial chylomicronemia25
• Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial23
• National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk18
• Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease17
• Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study15
• Relationship between LDL-C, estimated true LDL-C, apolipoprotein B- and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide14
• Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey14